Intravenous cyclophosphamide improves cardiac dysfunction in lupus myocarditis.
We describe a Chinese woman who developed severe heart failure 3 years from the onset of systemic lupus erythematosus (SLE). Endomyocardial biopsy confirmed lupus myocarditis, with focal infiltrates of small lymphocytes and some polymorphic neutrophils. The conventional treatment for cardiac failure plus oral prednisolone failed to bring clinical and echocardiographical improvement until the addition of intravenous (i.v.) 'pulse' cyclophosphamide. Three weeks after i.v. cyclophosphamide treatment, there was significant improvement of her heart failure symptoms with improvement in the ejection fraction from 19% to 63%.
Chan
Y K
YK
Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, PRC. alice_ykchan@yahoo.com.hk
Li
E K
EK
Tam
L S
LS
Chow
L T C
LT
Ng
H K
HK
D000328:Adult; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D006333:Heart Failure / Q000188:drug therapy / Q000209:etiology / Q000473:pathology; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D007275:Injections, Intravenous; D008180:Lupus Erythematosus, Systemic / Q000188:drug therapy* / Q000209:etiology / Q000473:pathology; D009205:Myocarditis / Q000188:drug therapy* / Q000209:etiology / Q000473:pathology; D009206:Myocardium / Q000473:pathology; D016896:Treatment Outcome
D007166:Immunosuppressive Agents; D003520:Cyclophosphamide